Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon
复制标题
DOI：
10.1097/00126334-200311010-00003
复制
发表时间：
2003-11-01
影响因子：
3.6
通讯作者：
Nerrienet, E
中科院分区：
文献类型：
--
作者：
Ayouba, A;Tene, G;Nerrienet, E
目的：确定奈韦拉平（NVP）用于预防围产期母婴传播（MTCT）的艾滋病病毒在雅温得，Cameroon.Design：这项研究是一个前瞻性的公共卫生试点计划，涵盖了3年的时间（2000年1月至2002年12月）。婴儿在出生后72小时内给予2 mg/kg NVP糖浆。NVP治疗的儿童定期随访，并检查HIV-1感染在6-8周和5-6个月，通过血浆病毒载量（VL）定量与bDNA system.Results：123名儿童被诊断为围产期HIV-1感染在6-8周和5-6个月。13名儿童（10.6% [13/123]; 95%置信区间，5.1-16）被感染并表现出高VL，通常> 500，000拷贝/mL。两名儿童在两个时间点均具有中间VL（50 - 3500拷贝/mL）。107名儿童（87%）被认为在6-8周龄时未感染。结论：我们的研究结果表明，NVP给药后6-8周的HIV-1母婴传播率不超过13%（16/123），从而证明了NVP在现实生活中降低HIV-1母婴传播风险的有效性。
Objective: To determine the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaounde, Cameroon.Design: The study was a prospective Public Health Pilot Program covering a 3-year period (January 2000-December 2002).Methods: Counseled and consenting HIV-1-positive pregnant women were given a single dose of NVP at the onset of labor. Babies were given 2 mg/kg NVP syrup within the first 72 hours of life. NVP-treated children were regularly followed up and examined for HIV-1 infection at 6-8 weeks and 5-6 months through plasma viral load (VL) quantification with the bDNA system.Results: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 weeks and 5-6 months. Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL. Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points. One hundred seven children (87%) were considered not infected at 6-8 weeks of age.Conclusions: Our results indicate that the HIV-1 MTCT rate 6-8 weeks after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.